Aytu BioPharma, Inc. (AYTU) Financials

AYTU Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 105.0 million 69.7 million
March 31, 2026 111.7 million 76.5 million
Dec. 31, 2025 122.0 million 107.8 million
Sept. 30, 2025 125.0 million 101.8 million

AYTU Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 4.4 million 146000
March 31, 2026 -4.2 million 148000
Dec. 31, 2025 3.7 million 283000
Sept. 30, 2025 -618000 114000

AYTU Net Income

No data available :(

AYTU Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 26.3 million 9.1 million 853000
March 31, 2026 26.7 million 9.5 million 1.1 million
Dec. 31, 2025 30.0 million 11.0 million 973000
Sept. 30, 2025 32.6 million 10.4 million -

AYTU Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 12.3 million
March 31, 2026 10.5 million
Dec. 31, 2025 10.0 million
Sept. 30, 2025 19.5 million

AYTU Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 12000 - 10.4 million 6.1 million
March 31, 2026 - - 10.9 million 5.9 million
Dec. 31, 2025 17000 - 11.1 million 6.0 million
Sept. 30, 2025 - - 10.2 million 5.3 million

AYTU Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 16.1 million 4.4 million
March 31, 2026 12.4 million 5.6 million
Dec. 31, 2025 15.2 million 6.1 million
Sept. 30, 2025 13.9 million 4.7 million

AYTU Revenue by Segment
Graph available only for paid members. Upgrade to see it.

AYTU

Price: $1.97

52 week price:
1.80
3.07

Earnings Per Share: -1.16 USD

Exchange: NCM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 55600

Ebitda: -9.2 million

Market Capitalization: 22.2 million

Links: